What is Adverum Biotechnologies Price-to-Operating-Cash-Flow?
As of today (2024-06-01), Adverum Biotechnologies's share price is $8.315.
Adverum Biotechnologies's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-8.19. Hence, Adverum Biotechnologies's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Adverum Biotechnologies's Price-to-Operating-Cash-Flow or its related term are showing as below:
During the past 12 years, Adverum Biotechnologies's highest Price-to-Operating-Cash-Flow Ratio was 243.74. The lowest was 159.38. And the median was 206.64.
Adverum Biotechnologies's Cash Flow from Operations per share for the
three
months ended in Mar. 2024 was $-1.41.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-8.19.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 1.10% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -3.90% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was -12.30% per year.
During the past 12 years, Adverum Biotechnologies's highest 3-Year average Operating Cash Flow per Share Growth Rate was 14.10% per year. The lowest was -183.30% per year. And the median was -7.80% per year.
Adverum Biotechnologies Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Adverum Biotechnologies's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adverum Biotechnologies Price-to-Operating-Cash-Flow Chart
|
Adverum Biotechnologies Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
|
- |
- |
- |
- |
- |
|
Adverum Biotechnologies Quarterly Data
|
|
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Adverum Biotechnologies's Price-to-Operating-Cash-Flow
For the Biotechnology subindustry, Adverum Biotechnologies's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adverum Biotechnologies's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adverum Biotechnologies's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Adverum Biotechnologies's Price-to-Operating-Cash-Flow falls into.
Adverum Biotechnologies Price-to-Operating-Cash-Flow Calculation
Adverum Biotechnologies's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 8.315 | / | -8.193 |
| = | |
Adverum Biotechnologies's Share Price of today is $8.315.
Adverum Biotechnologies's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.19.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Adverum Biotechnologies (LTS:0HA3) Business Description
Traded in Other Exchanges
Address
100 Cardinal Way, Redwood CIty, CA, USA, 94063
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
Adverum Biotechnologies (LTS:0HA3) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0HA3 has been successfully added to your